



THE PRESCRIBER E-LETTER

MassHealth Management of Antipsychotic Medications

MassHealth covers most generic antipsychotic medications without prior authorization (PA) within quantity limits. Several injectable brand antipsychotic medications are also available without PA, within quantity limits. MassHealth requires PA for all oral brand antipsychotic and non-preferred injectable brand antipsychotics. Approval criteria generally include appropriate diagnosis, trials of less costly alternatives, and dosing within quantity limits. MassHealth also requires PA for concomitant use of two or more antipsychotic medications. MassHealth also requires prior authorization with documentation of medical necessity for certain specific dosage formulations (e.g., select oral solutions, orally disintegrating tablets).

MassHealth Management of Oral Antipsychotic Medications - Effective January 5, 2026

No PA*

ariprazole solution, tablet
 chlorpromazine
 clozapine tablet
 fluphenazine
 haloperidol
 loxapine capsule
 lurasidone tablet
 molindone
 olanzapine ODT, tablet
 paliperidone tablet
 perphenazine
 pimozide
 quetiapine tablet, ER tablet
 risperidone ODT 0.25 mg, 0.5 mg, 1 mg, 2 mg
 risperidone solution, tablet
 thioridazine
 thiothixene
 trifluoperazine
 ziprasidone capsule

PA Required

amitriptyline/perphenazine
 aripiprazole ODT
 Oripza® (ariprazole film)
 Abilify Mycite® (ariprazole tablet with sensor)
 Saphris® (asenapine sublingual tablet)
 Rexulti® (brexpiprazole)^{PD}
 Vraylar® (cariprazine)^{PD}
 clozapine ODT
 Versacloz® (clozapine suspension)
 Fanapt® (iloperidone)
 Caplyta® (lumateperone)^{PD}
 olanzapine/fluoxetine
 Lybalvi® (olanzapine/samidorphan)
 Nuplazid® (pimavanserin)
 risperidone ODT 3 mg, 4 mg
 Cobenfy® (xanomeline/trospium)

*PA not required for claims within quantity limits and age restrictions

ER=extended release, ODT=orally disintegrating tablet, PD=preferred drug

Please see Therapeutic Class **Table 24** on the [MassHealth Drug List](#) for more information regarding MassHealth management of antipsychotic medications.

The Prescriber e-Letter is an update designed to enhance the transparency and efficiency of the MassHealth drug prior-authorization (PA) process and the MassHealth Drug List. Each issue highlights key clinical information and updates to the MassHealth Drug List. The Prescriber E-Letter was prepared by the MassHealth Drug Utilization Review Program and the MassHealth Pharmacy Program.